Merck

Merck, Samsung Bioepis ink biosimilars development agreement

Friday, February 22, 2013 11:45 AM

Global healthcare company Merck and Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, entered into an agreement to develop and commercialize multiple pre-specified and undisclosed biosimilar candidates.

More... »

Lycera, Merck ink autoimmune collaboration

Wednesday, February 13, 2013 11:01 AM

Lycera, a biopharmaceutical company focused on autoimmune diseases, has signed a collaboration agreement with Merck, to discover, develop and commercialize small-molecule therapies directed to selected novel targets being investigated for the treatment of a broad range of immune-mediated disorders.

More... »

$262M Pan-European drug discovery platform launched

Friday, February 8, 2013 10:48 AM

The European Lead Factory, a novel platform for innovative drug discovery, was launched Feb. 7 by an international consortium of 30 partners. The partnership, the first of its kind, is supported by the Innovative Medicines Initiative (IMI) and creates opportunities for the discovery of new medicines by providing public partners with an “industry-like” discovery platform to translate cutting-edge academic research into high-quality drug lead molecules on a scale and speed that was not possible previously.

More... »

FDA approves OTC Oxytrol for Women for overactive bladder

Monday, January 28, 2013 10:53 AM

The FDA has approved Merck’s Oxytrol for Women, the first over-the-counter treatment for overactive bladder in women ages 18 years and older. Oxytrol will remain available for men with overactive bladder by prescription only.

More... »

DIA names Stephen P. Spielberg editor-in-chief of TIRS journal

Friday, January 25, 2013 11:59 AM

DIA, a neutral, global, professional and member-driven association of nearly 18,000 professionals, announced the arrival of Stephen P. Spielberg, M.D., Ph.D., as editor-in-chief of the newly launched, official DIA peer-reviewed scientific journal, Therapeutic Innovation & Regulatory Science (TIRS).

More... »

Merck, GE Healthcare collaborate on imaging biomarkers for BACE inhibitor program

Wednesday, December 19, 2012 01:18 PM

Merck and GE Healthcare have formed a clinical study collaboration, license and supply agreement for use of [18F]Flutemetamol, an investigational positron emission tomography (PET) imaging agent, to support Merck's development of MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).

More... »

Former Merck Serono headquarters in Geneva could host a new Wyss Institute

Friday, December 7, 2012 01:43 PM

A dedicated consortium comprised of the École Polytechnique Fédérale de Lausanne (EPFL), the University of Geneva (UNIGE), Dr. Hansjörg Wyss and the Bertarelli family has developed a project to convert part of the former Merck Serono site in Geneva, Switzerland, into a multi-development facility.

More... »

UAE, Merck Serono, Neopharma form first pharmaceutical production agreement

Wednesday, December 5, 2012 11:35 AM

Merck Serono, a division of Germany-based Merck, and a local manufacturer, Neopharma, have formed the first partnership of its kind to locally produce Merck branded medication in the UAE for distribution across the Middle East.

More... »

Janssen R&D establishes global cross-pharma clinical trial Investigator Databank

Monday, November 19, 2012 10:18 AM

Janssen Research & Development, based in Raritan, N.J., has established a global cross-pharmaceutical Investigator Databank designed to improve efficiencies of industry-sponsored clinical trials. Merck and Eli Lilly are the first two companies to join Janssen in this effort.

More... »

Merck Serono, Auxogyn collaborate on Eeva Test

Friday, October 19, 2012 11:01 AM

Merck Serono, the biopharmaceutical division of Merck, and Auxogyn, a company focused on translating scientific discoveries in early embryo development into clinical tools, have entered into a strategic agreement focused on Auxogyn's proprietary Early Embryo Viability Assessment (Eeva) Test.

More... »